Eli Lilly and the Obesity Market: Sizing a Forecast That Keeps Getting Bigger
Every year the estimate for the 2030 obesity drug market gets revised higher, now near 130 billion dollars. Eli Lilly’s forecast rests on tirzepatide share plus two pipeline drugs, orforglipron and retatrutide, and a huge…